Veru (VERU) Debt-to-Equity : 0.28 (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Veru Debt-to-Equity?

Veru's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.87 Mil. Veru's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.34 Mil. Veru's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $51.60 Mil. Veru's debt to equity for the quarter that ended in Dec. 2023 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Veru's Debt-to-Equity or its related term are showing as below:

VERU' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.31 Max: 1
Current: 0.28

During the past 13 years, the highest Debt-to-Equity Ratio of Veru was 1.00. The lowest was 0.08. And the median was 0.31.

VERU's Debt-to-Equity is ranked worse than
63.62% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs VERU: 0.28

Veru Debt-to-Equity Historical Data

The historical data trend for Veru's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Debt-to-Equity Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

0.38

0.47

0.09

0.19

0.73

Veru Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.35	1.00	0.44	0.73	0.28

Competitive Comparison of Veru's Debt-to-Equity

For the Biotechnology subindustry, Veru's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veru's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Veru's Debt-to-Equity falls into.

Veru Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Veru's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.901	+	12.504)	/	19.678
	=	0.73

Veru's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.869	+	12.34)	/	51.602
	=	0.28

Veru (NAS:VERU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Veru Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Veru's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (VERU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Executives

Mario Eisenberger	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch	director, 10 percent owner	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun	director	48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner	director, 10 percent owner, officer: President and CEO	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco	officer: VP and CFO	515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro	director	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr	officer: CEO of FHC Division	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz	director	2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines	officer: CFO and COO	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune	director	THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish	director, officer: Chairman/Chief Exec. Officer